GRACE :: Lung Cancer


Dr West

Serum Tumor Markers in Lung Cancer Management

download as a pdf file Download PDF of this page

I’ve been meaning to write on tumor markers detectable in the blood for the management of lung cancer. These are proteins that are produced by some tumors, and the idea is that the levels of the tumor markers in the blood can potentially be used to monitor the status of the disease. For prostate-specific antigen in prostate cancer, carcinoembryonic antigen in colon cancer, CA19-9 in pancreatic cancer, and several others in breast or ovarian cancer, these markers have been well studied and are commonly used. The more commonly used tumor markers in lung cancer are CEA, and sometimes CA-125, as well as occasionally some others.

The problem is that there’s so little written and even carefully researched on these issues in lung cancer. In one very good clinical textbook on lung cancer, tumor markers are mentioned on just a couple of the >450 pages. The National Comprehensive Cancer Network (NCCN) guidelines for NSCLC and SCLC do not have any mention of tumor markers, and they really have no standard role in management or treatment, which is why the use of them is so variable in the real world. Many experts do not consider there to be any real role for tumor markers in lung cancer. There are some very highly regarded cancer centers that as a policy never check or use tumor markers in managing lung cancer.

There are several important limitations in the use of serum tumor markers. Several of the proteins seen on lung cancers are the same ones seen on other cancers, and CEA is also elevated in smokers without cancer, so they aren’t specific to lung cancer. Also, if a marker is going to be very helpful, it should be expressed on the vast majority of the cancers you’re following, but different cancers express different proteins or none at all (abstract here). However, there are so many proteins being studied by just a handful of groups in the world that there has never been a critical mass of consensus leading to any standards here. It’s basically individual preference and style of the oncologist that leads to whether tumor markers are checked and followed.

There are a few basic principles about tumor markers. Some studies have shown individual markers at the time of diagnosis to be predictive of better or worse long-term outcome in NSCLC (abstract here) or SCLC (abstract here). Here is a figure that goes back more than 20 years, from an article on the prognostic value of CEA in SCLC:

CEA and SCLC survival

We can say a few principles about tumor markers. There’s some limited evidence that certain ones can be predictive of worse outcomes if they’re elevated at diagnosis, but there is no routine recommendation for checking this. Some people are interested in using factors like elevated markers to help refine recommendations about which early stage patients should receive post-operative chemo or not, but similar work is being done on tumor gene signatures, proteins like ERCC1 expression on resected tumors, and other techniques. There is also some limited evidence that a rising CEA after surery can predict a recurrence before imaging picks it up (abstract here). So perhaps finding a rising CEA would lead me to do a scan earlier rather than later to document a recurrence, but the tough question is how that would really help. There are a few cases in which a recurrence is detected when its localized and still potentially treatable with curative intent, but unfortunately the clear majority of cases have recurrences distantly. So the earlier detection allows people to learn they have advanced disease more readily, but it doesn’t clearly improve treatment options or outcomes compared to finding out when you otherwise would without the head start of the blood test.

The other key question is on using serum tumor markers to follow response, such as in patients with more advanced disease. This is really not well studied at all, but there is some work that suggests that response of various tumor markers after four weeks on treatment such as Iressa is well correlated with subsequent imaging-based responses, as well as survival (abstract here). Other work has shown in a variety of tumors treated with a range of treatments that there is a good but not perfect correlation of tumor marker trends with response (abstract here). My take on the situation is similar to my view on use of PET scan results and standard uptake values (SUVs) in assessing response and making treatment decisions in lung cancer. CT scans are a much better studied standard, and I would personally be very reluctant to stop a treatment that is not associated with progression on CT just because a tumor marker or SUV is rising. If you have to try so hard to find progression that it doesn’t appear on a CT, which shows a lot of detail, I would be disinclined to abandon that treatment. We don’t have enough effective therapies in lung cancer that I would want to toss a treatment that is pretty much associated with stable disease too quickly. But I do think that they can give some useful early feedback that can give a sense of when the next scans should be done. I hope more research helps us integrate tumor markers intelligently into the practice of lung cancer, because I do think they could prove to be helpful once we clarify their role.

3 Responses to Serum Tumor Markers in Lung Cancer Management

  • Chanwit says:

    Dr. West, thanks for all the tumor marker details and links. I can get a little glimpse of the mysteries of tumor markers.

    Looking back at my notes, my wife’s CEA was in steady decline after dx and start of treatment. I don’t know if numbers are important but the first recorded CEA after WBR, Chest, and Pelvic radiation was 22.5. There was a steep deline for 4 months until it was below 3. There were many interruptions during chemo but the CEA still declined. I believe that the CEA decline was key to our oncologist continuation to treat in view of poor chemo. response.

    1 year down the road the liver met that had been stable progressed and the CEA correlated with an increase to 14. Change of treatment to Alimta and the CEA was down to 7.3 in 2 months (2 Alimta treatments)(no scans yet). Our radiation oncologist said he would look for additional CEA decline when she receives the Quadramet next week.

    My personal feelings about the CEA tumor marker is that we have anxiety when it’s on the rise and are more hopeful when it’s stays in decline. Declining CEA is kind of a reward for staying on treatment. – Chanwit

  • Dr West
    Dr. West says:


    I agree completely that tumor markers are a double-edged sword. They give us some good news early if the markers are declining, but on the way up, they cause a lot of anxiety and lead us to be rather tempted to make changes before the scans show any progression.

    I agree with the reward part, but then that means that a rising tumor marker can be an early cause for worry, suggesting to people that they’re getting worse even when they otherwise feel well.

    -Dr. West

  • Pingback: Understanding What Are Normal Psa Levels | normal psa levels | Prostate Health

Leave a Reply

Ask Us, Q&A
Lung/Thoracic Cancer Expert Content


download as a pdf file Download PDF of this page

GRACE Cancer Video Library - Lung Cancer Videos




2015 Acquired Resistance in Lung Cancer Patient Forum Videos

download as a pdf file Download PDF of this page

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
download as a pdf file Download PDF of this page

Subscribe to the GRACEcast Podcast on iTunes

download as a pdf file Download PDF of this page

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
   (Free Newsletter)

Other Resources

download as a pdf file Download PDF of this page

Biomedical Learning Institute